John L. Berk, MD

Professor, Medicine

John Berk
617.358.4774
72 E. Concord St Housman (R)

Biography

Expertise in Amyloidosis with specific emphasis in Familial and localized amyloid disease; pulmonary fibrosis.

Other Positions

  • Member, Pulmonary Center, Boston University
  • Assistant Director, Amyloidosis Center, Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
  • Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences

Education

  • Case Western Reserve University, MD
  • Wesleyan University, BA

Publications

  • Published on 6/2/2022

    Ando Y, Adams D, Benson MD, Berk JL, Planté-Bordeneuve V, Coelho T, Conceição I, Ericzon BG, Obici L, Rapezz C, Sekijima Y, Ueda M, Palladini G, Merlini G. Guidelines and new directions in the therapy and monitoring of ATTRv amyloidosis. Amyloid. 2022 Jun 02; 1-13. PMID: 35652823.

    Read at: PubMed
  • Published on 5/14/2022

    Prokaeva T, Joshi T, Klimtchuk ES, Gibson VM, Spencer B, Siddiqi O, Nedelkov D, Hu Y, Berk JL, Cuddy SAM, Dasari S, Chiu A, Choate LA, McPhail ED, Cui H, Chen H, Burks EJ, Sanchorawala V, Connors LH. A novel substitution of proline (P32L) destabilises ß2-microglobulin inducing hereditary systemic amyloidosis. Amyloid. 2022 May 14; 1-8. PMID: 35575118.

    Read at: PubMed
  • Published on 3/7/2022

    Kaku MC, Bhadola S, Berk JL, Sanchorawala V, Connors LH, Lau KHV. Neurological manifestations of hereditary transthyretin amyloidosis: a focus on diagnostic delays. Amyloid. 2022 Mar 07; 1-6. PMID: 35253562.

    Read at: PubMed
  • Published on 1/27/2022

    Siddiqi OK, Mints YY, Berk JL, Connors L, Doros G, Gopal DM, Kataria S, Lohrmann G, Pipilas AR, Ruberg FL. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid. 2022 Jan 27; 1-8. PMID: 35083944.

    Read at: PubMed
  • Published on 11/12/2021

    Benson MD, Berk JL, Dispenzieri A, Damy T, Gillmore JD, Hazenberg BP, Lavatelli F, Picken MM, Röcken C, Schönland S, Ueda M, Westermark P. Tissue biopsy for the diagnosis of amyloidosis: experience from some centres. Amyloid. 2022 Mar; 29(1):8-13. PMID: 34766859.

    Read at: PubMed
  • Published on 5/6/2021

    Brannagan TH, Auer-Grumbach M, Berk JL, Briani C, Bril V, Coelho T, Damy T, Dispenzieri A, Drachman BM, Fine N, Gaggin HK, Gertz M, Gillmore JD, Gonzalez E, Hanna M, Hurwitz DR, Khella SL, Maurer MS, Nativi-Nicolau J, Olugemo K, Quintana LF, Rosen AM, Schmidt HH, Shehata J, Waddington-Cruz M, Whelan C, Ruberg FL. ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable. Orphanet J Rare Dis. 2021 05 06; 16(1):204. PMID: 33957949.

    Read at: PubMed
  • Published on 2/26/2021

    Coelho T, Ando Y, Benson MD, Berk JL, Waddington-Cruz M, Dyck PJ, Gillmore JD, Khella SL, Litchy WJ, Obici L, Monteiro C, Tai LJ, Viney NJ, Buchele G, Brambatti M, Jung SW, St L O'Dea L, Tsimikas S, Schneider E, Geary RS, Monia BP, Gertz M. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. Neurol Ther. 2021 Jun; 10(1):375-389. PMID: 33638113.

    Read at: PubMed
  • Published on 12/9/2020

    Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, Boman K, Gundapaneni B, Patterson TA, Schwartz JH, Sultan MB, Maurer MS. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT. JACC Heart Fail. 2021 02; 9(2):115-123. PMID: 33309574.

    Read at: PubMed
  • Published on 11/16/2020

    Adams D, Polydefkis M, González-Duarte A, Wixner J, Kristen AV, Schmidt HH, Berk JL, Losada López IA, Dispenzieri A, Quan D, Conceição IM, Slama MS, Gillmore JD, Kyriakides T, Ajroud-Driss S, Waddington-Cruz M, Mezei MM, Planté-Bordeneuve V, Attarian S, Mauricio E, Brannagan TH, Ueda M, Aldinc E, Wang JJ, White MT, Vest J, Berber E, Sweetser MT, Coelho T. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study. Lancet Neurol. 2021 01; 20(1):49-59. PMID: 33212063.

    Read at: PubMed
  • Published on 8/7/2020

    Dyck PJB, Coelho T, Waddington Cruz M, Brannagan TH, Khella S, Karam C, Berk JL, Polydefkis MJ, Kincaid JC, Wiesman JF, Litchy WJ, Mauermann ML, Ackermann EJ, Baker BF, Jung SW, Guthrie S, Pollock M, Dyck PJ. Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis. Muscle Nerve. 2020 10; 62(4):509-515. PMID: 32654156.

    Read at: PubMed

View 97 more publications: View full profile at BUMC

View all profiles